TR200200764T2 - At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı - Google Patents

At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı

Info

Publication number
TR200200764T2
TR200200764T2 TR2002/00764T TR200200764T TR200200764T2 TR 200200764 T2 TR200200764 T2 TR 200200764T2 TR 2002/00764 T TR2002/00764 T TR 2002/00764T TR 200200764 T TR200200764 T TR 200200764T TR 200200764 T2 TR200200764 T2 TR 200200764T2
Authority
TR
Turkey
Prior art keywords
receptors
increase
treatment
receptor
diseases caused
Prior art date
Application number
TR2002/00764T
Other languages
English (en)
Inventor
Rosemary Bullock Gillian
De Gasparo Marc
Maria Ganter Sabina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200764(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200200764T2 publication Critical patent/TR200200764T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bulus, sub-epitelial alandaki AT1 reseptörlerinin artisi veya epiteliadaki AT2 reseptörlerinin artisinin neden oldugu hastaliklarin ya da durumlarin tedavisi için farmasötik bir properasyon üretmek amaciyla sirasiyla bir AT1 reseptör antagonistinin ya da bir AT2 reseptör modülatörünün ya da onun farmasötik olarak uygun bir tuzunun kullanimi ile ilgilidir.
TR2002/00764T 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı TR200200764T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98811257 1998-12-23
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors

Publications (1)

Publication Number Publication Date
TR200200764T2 true TR200200764T2 (tr) 2002-07-22

Family

ID=26152118

Family Applications (7)

Application Number Title Priority Date Filing Date
TR2006/05471T TR200605471T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
TR2008/05740T TR200805740T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2008/05741T TR200805741T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
TR2002/00764T TR200200764T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
TR2008/05275T TR200805275T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2001/01784T TR200101784T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı.
TR2006/05472T TR200605472T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@

Family Applications Before (3)

Application Number Title Priority Date Filing Date
TR2006/05471T TR200605471T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
TR2008/05740T TR200805740T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2008/05741T TR200805741T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@

Family Applications After (3)

Application Number Title Priority Date Filing Date
TR2008/05275T TR200805275T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2001/01784T TR200101784T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı.
TR2006/05472T TR200605472T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@

Country Status (26)

Country Link
EP (3) EP2298298A3 (tr)
JP (2) JP2002533390A (tr)
KR (1) KR100646716B1 (tr)
CN (2) CN1636561A (tr)
AT (2) ATE524176T1 (tr)
AU (4) AU3043000A (tr)
BR (1) BR9916576A (tr)
CA (2) CA2351357A1 (tr)
CY (2) CY1106581T1 (tr)
CZ (2) CZ293257B6 (tr)
DE (1) DE69935249T2 (tr)
DK (2) DK1588706T3 (tr)
ES (2) ES2281978T3 (tr)
HK (1) HK1038888B (tr)
HU (1) HUP0104780A3 (tr)
ID (1) ID29856A (tr)
IL (5) IL143233A0 (tr)
NO (2) NO328775B1 (tr)
NZ (3) NZ511938A (tr)
PL (1) PL199100B1 (tr)
PT (2) PT1588706E (tr)
RU (3) RU2271809C2 (tr)
SI (2) SI1588706T1 (tr)
SK (1) SK9132001A3 (tr)
TR (7) TR200605471T2 (tr)
WO (1) WO2000038676A1 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072049A3 (en) * 2000-06-22 2009-12-30 Novartis Ag Solid valsartan pharmaceutical compositions
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (fr) * 2001-04-09 2002-10-24 Tokai University Educational System Compositions inhibant la modification proteique
ATE372987T1 (de) 2001-05-31 2007-09-15 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1444988A4 (en) * 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EA008063B1 (ru) * 2003-11-03 2007-02-27 Зентива А.С. Рецептура, содержащая валсартан (valsartan)
AU2005318365B2 (en) 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
US7795275B2 (en) * 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110027358A1 (en) * 2007-03-29 2011-02-03 Rajesh Kshirsagar Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
EP4186491A1 (en) * 2007-11-06 2023-05-31 Novartis AG Pharmaceutical compositions
US20110104166A1 (en) * 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
DE10075018I2 (de) 1989-06-14 2001-08-09 Smithkline Beecham Corp Imidazoalkensäure.
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
EP0551432A1 (en) * 1990-10-02 1993-07-21 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
AU685767B2 (en) 1992-12-11 1998-01-29 Novartis Ag Substituted benzazepinones
KR950704280A (ko) 1992-12-11 1995-11-17 베르너 발데크 벤즈아제피논 유도체(Benzazepinone Derivatives)
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0750500A1 (en) 1994-03-17 1997-01-02 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
PT853477E (pt) 1995-10-06 2003-01-31 Novartis Ag Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
PT883401E (pt) * 1996-02-29 2003-03-31 Novartis Ag Antagonista do receptor at1 para estimulacao da apoptose
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
IL140665A0 (en) 1998-07-10 2002-02-10 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
CZ20012682A3 (cs) * 1999-01-26 2001-10-17 Novartis Ag Pouľití antagonistů receptoru angiotensinu II pro léčení akutního infarktu myokardu
EP2072049A3 (en) * 2000-06-22 2009-12-30 Novartis Ag Solid valsartan pharmaceutical compositions
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
ES2281978T3 (es) 2007-10-01
DK1140071T3 (da) 2007-06-04
ID29856A (id) 2001-10-18
NO20100041L (no) 2001-08-16
SI1140071T1 (sl) 2007-08-31
RU2005124363A (ru) 2007-02-10
EP2298298A3 (en) 2011-05-11
ATE524176T1 (de) 2011-09-15
IL143233A0 (en) 2002-04-21
DE69935249D1 (de) 2007-04-05
RU2271809C2 (ru) 2006-03-20
CA2351357A1 (en) 2000-07-06
NZ553010A (en) 2008-09-26
KR20010089681A (ko) 2001-10-08
IL143233A (en) 2007-07-24
EP2298298A2 (en) 2011-03-23
CN1304000C (zh) 2007-03-14
NO20013143L (no) 2001-08-16
PL349424A1 (en) 2002-07-29
EP1588706A3 (en) 2005-12-07
JP2002533390A (ja) 2002-10-08
AU2006203077B2 (en) 2009-10-08
BR9916576A (pt) 2001-10-02
NO20013143D0 (no) 2001-06-22
TR200605472T1 (tr) 2007-02-21
TR200605471T2 (tr) 2006-11-21
EP1140071A1 (en) 2001-10-10
KR100646716B1 (ko) 2006-11-17
IL179016A0 (en) 2007-03-08
SK9132001A3 (en) 2002-01-07
EP1140071B1 (en) 2007-02-21
HUP0104780A2 (hu) 2002-04-29
CZ293257B6 (cs) 2004-03-17
NO328775B1 (no) 2010-05-10
AU3043000A (en) 2000-07-31
AU2009220022B2 (en) 2011-11-03
CA2622805C (en) 2011-05-10
RU2361575C2 (ru) 2009-07-20
DK1588706T3 (da) 2012-01-16
TR200101784T2 (tr) 2001-10-22
CN1636561A (zh) 2005-07-13
AU2003266433A1 (en) 2004-01-08
CZ20012306A3 (cs) 2001-12-12
PL199100B1 (pl) 2008-08-29
EP1588706B1 (en) 2011-09-14
ATE354364T1 (de) 2007-03-15
ES2373556T3 (es) 2012-02-06
HK1038888B (zh) 2007-09-21
AU2009220022A1 (en) 2009-10-15
RU2008143545A (ru) 2010-05-10
CY1112395T1 (el) 2015-12-09
HUP0104780A3 (en) 2002-11-28
IL179017A0 (en) 2007-03-08
CN1331590A (zh) 2002-01-16
PT1140071E (pt) 2007-05-31
EP1588706A2 (en) 2005-10-26
JP5254258B2 (ja) 2013-08-07
HK1038888A1 (en) 2002-04-04
SI1588706T1 (sl) 2012-01-31
CY1106581T1 (el) 2012-01-25
IL179015A0 (en) 2007-03-08
WO2000038676A1 (en) 2000-07-06
NZ511938A (en) 2004-02-27
CA2622805A1 (en) 2000-07-06
CZ297795B6 (cs) 2007-03-28
PT1588706E (pt) 2011-12-21
AU2003266433B2 (en) 2006-08-10
AU2006203077A1 (en) 2006-08-10
TR200805741T2 (tr) 2008-10-21
DE69935249T2 (de) 2007-10-31
TR200805275T2 (tr) 2008-09-22
JP2010090169A (ja) 2010-04-22
NZ587909A (en) 2012-05-25
TR200805740T1 (tr) 2010-06-21

Similar Documents

Publication Publication Date Title
TR200200764T2 (tr) At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
BG66085B1 (bg) Фенилаланинови производни
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
ATE353875T1 (de) Indolderivate
DK1237584T3 (da) Receptorbindende konjugater
AP1402A (en) Prevention of migraine recurrence.
PT1146872E (pt) Utilizacao de antagonistas do receptor de angiotensina ii para tratamento de enfarte agudo do miocardio.
DK0883401T3 (da) AT1-receptorantagonist til stimulering af apoptose
TR200103827T2 (tr) Farmakolojik kompleks
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
MY131858A (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
HUP9900606A2 (hu) 5-HT3 Receptor antagonisták mozgászavar kezelésére